20 recruiting. 20 Phase 2, 6 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Recruiting 20 |
| Phase 1 | 6 | Recruiting 6 |
| Phase 3 | 4 | Recruiting 4 |
Follow Type 1 Diabetes: new trials by email Literature Review of Type 1 Diabetes trials Research Report on Type 1 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Semaglutide, Placebo - Type 1 Diabetes, Overweight , Obesity | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 40 | 2026-10-13 | 2026-10-23 |
| A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar Tirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Carbohydrate Counting - Type 1 Diabetes, Type 1 Diabetes Mellitus | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 105 | 2026-05-19 | 2026-05-27 |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab - Type 1 Diabetes, New Onset | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 120 | 2026-03-10 | 2026-10-16 |
| The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation Colchicin 0.5 mg once daily for two weeks, then twice daily for two weeks, Placebo once daily for two weeks, then twice daily for two weeks, Colchicine tablet 0.5 mg once-daily for two weeks, then twice daily for two weeks - Type 1 Diabetes, Chronic Inflammation | Phase 2 | Recruiting | Asger Lund, MD | 26 | 2025-12-01 | 2025-12-23 |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes High Dose SAB-142, Low Dose SAB-142, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | SAb Biotherapeutics, Inc. | 159 | 2025-11-25 | 2026-10-13 |
| Precision Administration of Anti-thymocyte Globulin With or Without Verapamil Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | University of Florida | 60 | 2025-11-12 | 2025-11-26 |
| The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes Liraglutide Pen Injector, Saline Injections - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-10-03 | 2026-10-19 |
| A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil Verapamil (Part A), Placebo - Type 1 Diabetes | Phase 1 / Phase 2 | Recruiting | Johnny Ludvigsson | 36 | 2025-08-06 | 2025-09-30 |
| A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus OPF-310 - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Recruiting | Otsuka Pharmaceutical Factory, Inc. | 13 | 2025-06-10 | 2026-08-21 |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) CNP-103, Placebo - Type 1 Diabetes Mellitus, T1D | Phase 1 / Phase 2 | Recruiting | COUR Pharmaceutical Development Company, Inc. | 72 | 2025-05-12 | 2026-09-11 |
| Denosumab for Type 1 Diabetes Denosumab, Placebo - Type 1 Diabetes | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 45 | 2025-05-05 | 2026-10-20 |
| Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes Insulin producing stem cells infusion - Stem Cells, Type 1 Diabetes | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 20 | 2025-04-01 | 2025-04-30 |
| Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes Sotagliflozin, Placebo - Type 1 Diabetes, Heart Failure | Phase 2 | Recruiting | University of Dundee | 320 | 2025-01-28 | 2026-04-06 |
| Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide Semaglutide with 4 meal strategies, Placebo with 4 meal strategies - Type 1 Diabetes, Diabetes Mellitus | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 26 | 2024-12-01 | 2024-12-18 |
| Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial Acetazolamide, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | University of California, San Diego | 25 | 2024-08-14 | 2025-06-17 |
| Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes Semaglutide, Placebo - Diabetic Kidney Disease, Type 1 Diabetes | Phase 2 | Recruiting | University of Washington | 60 | 2024-04-05 | 2026-06-02 |
| Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes CELZ-201 Administration, Control Group - Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 1 / Phase 2 | Recruiting | Creative Medical Technology Holdings Inc | 18 | 2023-04-07 | 2026-02-19 |
| The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Metformin - Type 1 Diabetes, Obesity | Phase 2 | Recruiting | Heba M. Ismail | 114 | 2022-09-30 | 2026-08-21 |
| Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Cyclosporin, ILT101, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 24 | 2022-09-21 | 2026-09-09 |
| ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes ACT1VATE, DSME/S - Type 1 Diabetes | Phase 2 | Recruiting | Scripps Whittier Diabetes Institute | 250 | 2021-10-25 | 2026-05-29 |
Diabetes Mellitus, Type 1 (20) · Diabetes Mellitus (4) · Insulin Resistance (2) · Obesity (2) · Overweight (2) · Autoimmune Diseases (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Glucose Metabolism Disorders (1) · Heart Failure (1) · Hypoglycemia (1) · Immune System Diseases (1) · Metabolic Diseases (1)
Endocrine System Diseases (20) · Nutritional and Metabolic Diseases (20) · Autoimmune Diseases (19) · Glucose Metabolism Disorders (19) · Immune System Diseases (19) · Metabolic Diseases (19) · Diabetes Mellitus (16) · Body Weight (3) · Nutrition Disorders (3) · Overnutrition (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Hyperinsulinism (2) · Cardiovascular Diseases (1) · Diabetes Complications (1)
semaglutide (3) · Antilymphocyte Serum (2) · Verapamil (2) · thymoglobulin (2) · (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1) · Acetazolamide (1) · Adalimumab (1) · Colchicine (1) · Control Groups (1) · Cyclosporine (1) · Denosumab (1) · Liraglutide (1) · Metformin (1) · Saline Solution (1) · Therapeutics (1)
McGill University Health Centre/Research Institute of the McGill University Health Centre (3) · City of Hope Medical Center (2) · Ain Shams University (1) · Asger Lund, MD (1) · Assistance Publique - Hôpitaux de Paris (1) · COUR Pharmaceutical Development Company, Inc. (1) · Creative Medical Technology Holdings Inc (1) · Heba M. Ismail (1) · Johnny Ludvigsson (1) · Mayo Clinic (1) · Otsuka Pharmaceutical Factory, Inc. (1) · SAb Biotherapeutics, Inc. (1) · Scripps Whittier Diabetes Institute (1) · University of California, San Diego (1) · University of Dundee (1)
United States (12) · Canada (4) · Denmark (2) · France (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Egypt (1) · Finland (1) · Germany (1) · Italy (1) · Lithuania (1) · New Zealand (1) · Poland (1)
Melissa-Rosina Pasqua, MD, PhD (2) · Addie Fortmann, PhD (1) · Adrian Vella, MD (1) · Ahmad Haidar, PhD (1) · Alberto Pugliese, MD (1) · Asger B Lund, MD, PhD (1) · Athena Philis-Tsimikas, MD (1) · David Cherney, PhD, MD (1) · David Klatzmann, MD, Ph.D (1) · Fouad Kandeel, MD, PhD (1) · Francesco Vendrame, MD (1) · Ian de Boer, MD, MS (1) · Ify Mordi, MBChB, MD (1) · Irl Hirsch, MD (1)
PMID 29988125, PMID 30012675, PMID 33632742, PMID 38117469, PMID 39265782, PMID 40693871
2025 (2), K23DK129799 (1), R01DK127491 (1)